AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Bogdanoff who wrote (506)	8/19/1997 11:26:00 AM
From: David Bogdanoff	of 2173

A few comments on CEO Haugens talk on CNBC this morning. He felt that the market overreacted to the company's press release. Explained that there were four endpoints for six studies (3 type 1, 3 type 2) and there was a problem with one endpoint (insulin) for type 2 diabetes in one of the two reported studies. Also they made protocol adjustments in remaining four studies to control for insulin intake and to select on a subgroup of patients. Apparently this reflects the results of the first two studies. He also said they would continue to analyze the data from the first two studies and had another hormone headed for clinicals at end of 98, and an artheriosclerosis drug headed for clinicals in early 99. My view is that they mishandled the news release, causing or at least contributing to the overreaction, and their clinical trial program is mishandled. They should have controlled for variable insulin intake to begin with. They should not be adjusting the protocol after enrollment has started. And they should state what their primary endpoint is. Comments anyone? David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next